Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/40485
Title: | Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. | Authors: | Aleksova J.;McArthur G.;Soldatos G. ;Lau P.K.H. | Institution: | (Aleksova) Monash Health, Clayton, VIC, Australia (Lau, Soldatos) Peter MacCallum Cancer Institute, Cancer Medicine, East Melbourne, VIC, Australia (Soldatos) Monash Centre for Health Research and Implementation, Melbourne, VIC, Australia (McArthur) Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia (McArthur) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia | Issue Date: | 29-Dec-2016 | Copyright year: | 2016 | Publisher: | BMJ Publishing Group (E-mail: subscriptions@bmjgroup.com) | Place of publication: | United Kingdom | Publication information: | BMJ Case Reports. 2016 (no pagination), 2016. Article Number: 217454. Date of Publication: 2016. | Journal: | BMJ Case Reports | Abstract: | Immune checkpoint inhibitors offer patients with advanced melanoma substantial improvements in survival. Unlike chemotherapy, immune checkpoint inhibitors such as ipilimumab and pembrolizumab cause unique immune-related adverse events (irAEs), including the development of endocrinopathies. We report a case of a man aged 60 years who developed diabetic ketoacidosis (DKA) following the use of pembrolizumab for the treatment of metastatic melanoma. He received four cycles of ipilimumab, before proceeding to pembrolizumab. Five weeks after initiating pembrolizumab, he presented in DKA with a pH of 7.0, bicarbonate of 7 mmol/L, blood glucose of 27 mmol/L and serum ketones of 5.9 mmol/L. Antibodies to glutamic acid decarboxylase (anti-GAD) and Islet antigen 2 (IA-2) were negative and C-peptide was low at 57 pmol/L (300-2350 pmol/L). There was no personal or family history of autoimmune conditions. Standard immunosuppression for irAEs was started using prednisolone in an attempt to salvage beta cell function but was unsuccessful. To the best of our knowledge, this is the first reported attempt at reversing pembrolizumab-induced type 1 diabetes using glucocorticoids.Copyright © 2016 BMJ Publishing Group Ltd. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/bcr-2016-217454 | PubMed URL: | 27881588 [http://www.ncbi.nlm.nih.gov/pubmed/?term=27881588] | ISSN: | 1757-790X (electronic) | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/40485 | Type: | Article | Type of Clinical Study or Trial: | Case series or case report |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.